Massachusetts-based Theracos – not to be confused with Bay Area diagnostics company Theranos – just raised $25 million for its type 2 diabetes drug.
The company is developing a series of SGLT2 inhibitors as a potential drug to treat type 2 diabetes. It works by inhibiting the kidney’s ability to recover glucose that’s been excreted – thereby increasing the amount that is shed in urine, and decreasing the amount retained in the blood.
How to Optimize Your Phlebotomy Setup for Efficient Patient Care
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
The company is currently in the midst of recruiting participants with type 2 diabetes for a Phase 2b dosing trial. Its experimental drug, called bexagliflozin, has been tested in studies in the U.S., Europe, Russia and Japan.
It works in a similar manner to Farxiga, a popular AstraZeneca type 2 diabetes drug approved in 2014 that also works as an SGLT2 inhibitor. Other such drugs are Invokana and Jardiance.
[Image courtesy of Flickr user Bill David Brooks]